Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HRAS | P01112 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542628 | 1.00 | MAPK1 (0.58) | MAPK1POLBHRASMEN1KMT2A | |
| SCHEMBL7150940 | 1.00 | MAPK1 (0.58) | MAPK1POLBHRASMEN1KMT2A | |
| SCHEMBL13031052 | 1.00 | MAPK1 (0.58) | MAPK1POLBHRASMEN1KMT2A | |
| SCHEMBL5841792 | 1.00 | MAPK1 (0.58) | MAPK1POLBHRASMEN1KMT2A | |
| SCHEMBL14520980 | 1.00 | MAPK1 (0.58) | MAPK1POLBHRASMEN1KMT2A | |
| SCHEMBL542635 | 1.00 | MAPK1 (0.58) | MAPK1POLBHRASMEN1KMT2A | |
| SCHEMBL14544300 | 1.00 | MAPK1 (0.58) | MAPK1POLBHRASMEN1KMT2A | |
| SCHEMBL542627 | 1.00 | MAPK1 (0.58) | MAPK1POLBHRASMEN1KMT2A | |
| SCHEMBL21097246 | 1.00 | MAPK1 (0.58) | MAPK1POLBHRASMEN1KMT2A | |
| SCHEMBL20643560 | 1.00 | MAPK1 (0.58) | MAPK1POLBHRASMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025027624-A1 | CYCLIC GLYCOLIPOPEPTIDE VACCINE ADJUVANTS AND THE PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2025-02-06 | — | — | WO | disclosed |
| EP-3389643-B1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | BHARAT BIOTECH INT LTD (IN) | 2023-05-03 | — | — | EP | disclosed |
| EP-3387005-B1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | BHARAT BIOTECH INT LTD (IN) | 2022-08-24 | — | — | EP | disclosed |
| US-20220056080-A1 | Muramyl Peptide Derivatives | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2022-02-24 | — | — | US | disclosed |
| US-10927147-B2 | Muramyl peptide derivative compound, synthesis and uses thereof | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2021-02-23 | — | — | US | disclosed |
| US-10576147-B2 | Muramyl peptide derivative compound, synthesis and uses thereof | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2020-03-03 | — | — | US | disclosed |
| US-20180371023-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2018-12-27 | — | — | US | disclosed |
| US-20180360957-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2018-12-20 | — | — | US | disclosed |
| CN-108884132-A | Novel muramyl peptide derivative compound, its synthesis and application thereof | 巴拉特生物技术国际有限公司 | 2018-11-23 | — | — | CN | disclosed |
| EP-3389643-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | Bharat Biotech International Limited (IN) | 2018-10-24 | — | — | EP | disclosed |
| US-5759823-A | MIXING IN AQUEOUS MEDIUM ACTIVATED DONOR MONOSACCHARIDE WITH ACCEPTOR SACCHARIDE IN PRESENCE OF GLYCOSYLTRANSFERASE, MAINTAINING TO GLYCOSYLATE ACCEPTOR SACCHARIDE | SCRIPPS RESEARCH INSTITUTE (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0439585-B1 | IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS | MAG GEORG MAYRHOFER & CO OHG (AT) | 1997-10-29 | — | — | EP | disclosed |
| US-5593887-A | Oligosaccharide enzyme substrates and inhibitors: methods and compositions | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0576592-A4 | OLIGOSACCHARIDE ENZYME SUBSTRATES AND INHIBITORS: METHODS AND COMPOSITIONS | SCRIPPS RESEARCH INST (US) | 1996-01-24 | — | — | EP | disclosed |
| US-5461143-A | Oligosaccharide enzyme substrates and inhibitors: methods and compositions | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0576592-A1 | OLIGOSACCHARIDE ENZYME SUBSTRATES AND INHIBITORS: METHODS AND COMPOSITIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-05 | — | — | EP | disclosed |
| US-5196478-A | Polystyrene, assays | EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) | 1993-03-23 | — | — | US | disclosed |
| WO-1992016640-A1 | OLIGOSACCHARIDE ENZYME SUBSTRATES AND INHIBITORS: METHODS AND COMPOSITIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0439585-A1 | IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS. | EPIPHARM ALLERGIE SERVICE (AT) | 1991-08-07 | — | — | EP | disclosed |
| WO-1991002768-A1 | IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS | EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) | 1991-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056080-A1 | Muramyl Peptide Derivatives | NOD2, NGLY1, LNPEP | MAPK1 1159/4885POLB 613/4885HRAS 4315/4885 |
| US-20180360957-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | NOD2, HM13, HLA-DRB1 | MAPK1 877/4885POLB 958/4885HRAS 2804/4885 |
| US-10576147-B2 | Muramyl peptide derivative compound, synthesis and uses thereof | NOD2, HM13, QRFPR | MAPK1 807/4885POLB 750/4885HRAS 2764/4885 |
| US-20180371023-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | NOD2, MICA, TLR9 | MAPK1 1034/4885POLB 1223/4885HRAS 4473/4885 |
| US-10927147-B2 | Muramyl peptide derivative compound, synthesis and uses thereof | NOD2, TLR9, MICA | MAPK1 960/4885POLB 817/4885HRAS 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.